Risk assessment: Seasonal influenza 2011–2012 in Europe (EU/EEA countries)
ECDC produces an annual risk assessment for the seasonal influenza epidemics in Europe. This is following both a recommendation in the report on the handling of the 2009 pandemic adopted by the World Health Assembly in May 2011 and the model developed by ECDC during that pandemic. The first EU seasonal influenza risk assessment was published in January 2011, following the start of the influenza season in late November 2010. In 2012, the season started later than in most years, with the first five countries exceeding their epidemic threshold in week 3/2012.
Risk assessment: Seasonal influenza 2013–2014 in the EU/EEA countries
This document is a routine and planned risk assessment of the 2013-2014 seasonal influenza in EU/EEA countries. Active circulation of influenza has started late in Europe in the 2013-2014 season, with a different timing across EU/EEA countries, states the annual ECDC risk assessment on seasonal influenza.
Risk assessment: Seasonal influenza 2014–2015 in the EU/EEA countries
This risk assessment covers the 2014–2015 influenza season in the European Union and European Economic Area (EU/EEA).
Risk assessment: Seasonal influenza 2012/13 in Europe (EU/EEA countries)
ECDC has produced an annual risk assessment of the seasonal influenza epidemics in Europe since the 2010/11 season following the model developed by ECDC during the 2009 pandemic. It gives an early description of the influenza season in the countries affected earliest, providing guidance and information to countries that are affected later, as influenza progresses across Europe over several months. It describes any specifics of the season, particularly in areas where public health or clinical actions are envisaged, as well as highlights areas of uncertainty where further work is required.
Threat Assessment Brief: Eurasian avian-like A(H1N1) swine influenza viruses
A recently published study conducted between 2011 and 2018 in China, and based on surveillance data in pigs, identified an emerging genotype 4 (G4) reassortant Eurasian avian-like (EA) A(H1N1) swine influenza virus that contains internal genes from the human A(H1N1)pdm09 and North American triple-reassortant (TR) lineage-derived internal genes.
Risk assessment update: seasonal influenza, EU/EEA, 2016–2017
This updated risk assessment provides an overview of the current influenza situation in Europe.
Regional situation assessment - Seasonal influenza, 2019–2020
This situation update for seasonal influenza uses epidemiological and virological data to assess the seasonal increase of influenza cases in relation to disease severity and impact on healthcare systems. It is designed to assist forward planning in Member States.
Rapid risk assessment: Influenza-associated invasive pulmonary aspergillosis, Europe
This report assesses the risk of invasive pulmonary aspergillosis (IPA) among patients with severe influenza in hospital intensive care units in the European Union (EU)/European Economic Area (EEA)
Rapid Risk Assessment: Public health risks related to communicable diseases during the Hajj 2017, Saudi Arabia, 30 August – 4 September 2017
This document assesses the potential risk of outbreaks and transmission of communicable diseases during the Hajj taking place between 30 August and 4 September 2017.
Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children
Several countries affected by the coronavirus disease (COVID-19) pandemic recently reported cases of children that were hospitalised in intensive care due to a rare paediatric inflammatory multisystem syndrome (PIMS). The presenting signs and symptoms are a mix of the ones for Kawasaki disease (KD) and toxic shock syndrome (TSS) and are characterised, among others, by fever, abdominal pain and cardiac involvement. A possible temporal association with SARS-COV-2 infection has been hypothesised because some of the children that were tested for SARS-CoV-2 infection were either positive by polymerase chain reaction (PCR) or serology.